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Fig. S1. Effects of gain and loss of EGFR signaling on sleep architecture. Fig. S2 . Amino acid alignment of human and zebrafish TGFa, EGF, and EGFR. Fig. S3 . Gefitinib does not enhance egfra -/phenotype and effects of EGFR inhibitors on sleep architecture. Fig. S4 . EGFR signaling is not required for behavioral circadian rhythms. Fig. S5 . Validation of an SD assay, and EGFR signaling is required for normal homeostatic regulation of sleep. Fig. S6 . Inhibition of MAPK/ERK signaling suppresses TGFa overexpression-induced sleep. Fig. S7 . EGFR signaling regulates npvf expression, and TGFa overexpression-induced sleep is suppressed in npvf mutant animals. Fig. S8 . Association of ERBB4 sleepiness allele with increased ERBB4 expression in humans and pharmacological inhibition of KSR2 or ERBB4 decrease sleep in zebrafish. Table S1 . Variants at ERBB4 and KSR2 associate with self-reported measures of sleep quality and quantity in U.K. Biobank subjects. Table S2 . Descriptive characteristics of U.K. Biobank subjects of European ancestry used for sleep trait analysis. TGFa Dr mut has a 7 bp deletion after amino acid 8, resulting in a translational frame shift that generates a predicted protein that lacks both of these domains. EGF Dr mut has a 26 bp insertion after amino acid 142, resulting in a translational frame shift that generates a predicted protein that lacks 5 EGF domains and the TMD. EGFRa Dr mut contains an 11 bp deletion and 27 bp insertion after amino acid 264, resulting in a translational frame shift before the TMD and intracellular domains required to interact with downstream effectors. Colors indicate amino acids with similar chemical properties. Grey shading indicates frame shifted sequence in mutant proteins. Fig. S5 . Validation of an SD assay, and EGFR signaling is required for normal homeostatic regulation of sleep. (A) Sleep behavioral traces for WT animals that were sleep deprived during the first 6 h of night at 7-dpf (P, orange) followed by a period of recovery sleep during the remaining 4 h of night (RS, purple) (red trace), as well as their non-perturbed siblings (blue trace). (B-D) Quantification of sleep during the night before the night perturbation (N6: 6-dpf), during the 4 h immediately after the night perturbation (RS: last 4 h of night at 7-dpf), and during the night after the night perturbation (N8: night of 8-dpf). Night perturbed animals showed significantly more sleep than non-perturbed controls only during the SR period (C). (E) Sleep behavioral traces for WT animals that were perturbed for 6 h during the middle of the day (ZT2-ZT8) at 7-dpf (P, orange) followed by a 4 h period of recovery sleep (RS) immediately thereafter, during which time they were monitored in the dark (red trace), as well as their non-perturbed siblings (blue trace). Animals were maintained in constant dark for the remainder of the experiment. (F-H) Quantification of sleep during the night before the day perturbation (N6: 6dpf), during the 4 h immediately after the day perturbation (RS: 4 hours of subjective day at 7dpf), and during the night after the day perturbation (N7: night of 7-dpf). There was no significant difference in the amount of sleep between perturbed and non-perturbed animals during any of these time periods. (I) Normalized sleep rebound following perturbation during the day or night for WT animals. Normalized sleep rebound is calculated as the amount of sleep of each perturbed animal during the first 4 h of recovery sleep (RS, purple) divided by the average amount of sleep of all non-perturbed control animals during this time period. (J-O) Further quantification of gefitinib sleep deprivation experiment ( Fig. 3D-3G Results for the following traits were looked up from GWAS summary statistics available at Sleep Disorder Knowledge Portal (http://sleepdisordergenetics.org/): Self-report Sleep duration (5), Daytime sleepiness (4); Frequent insomnia symptoms (7) and Chronotype (8). 
